Oncology ESMO25: Harnessing the innate and the adaptive immune respon... As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.
Oncology ESMO25: On next-generation bispecifics, with Tadaaki Taniguc... At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas.
R&D ESMO25: On partnerships between pharma and diagnostic develo... Jane Li, Senior Director of Pharma CDx and CRO Partnership, Clinical Next Generation Sequencing Business, at Thermo Fisher Scientific discusses CDx.
Oncology 5 clinical advances and related implications from ESMO 2025 5 particularly insightful takeaways from this year’s ESMO Congress that merit deeper reflection on where cancer care can go.
Oncology ESMO25: Immuno-therapies and translational research in oncol... Dr Inge Marie Svane – Professor in Clinical cancer immune therapy and director of the translational research centre, CCIT, on IO Biotech's ESMO25 data
Oncology ESMO25: The changing landscape of rare oncology, with Jan Ki... ESMO sees many presentations on cancers of the lung, breast, and bladder - for example - but this year there was meaningful data in rare cancers, too.
R&D Working together to innovate on pragmatic clinical trials, w... In today’s episode, host Jonah Comstock speaks with Rob DiCicco, vice president of portfolio management at TransCelerate Biopharma.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.